News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Invivyd
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
May 07, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
May 02, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
April 30, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
April 15, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces CEO Transition
April 12, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
April 04, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
March 28, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
March 22, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
March 22, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
January 03, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
December 18, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate in Upcoming Investor Conferences
October 31, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
September 11, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate in Upcoming Investor Conferences
September 06, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Appoints William Duke as Chief Financial Officer
September 05, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
August 10, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
July 27, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
July 17, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
June 26, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
June 22, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate at the Jefferies Healthcare Conference
June 01, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
May 04, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
April 25, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close